{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T23:21:42Z","timestamp":1770420102150,"version":"3.49.0"},"reference-count":0,"publisher":"MJH Life Sciences","issue":"3411","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.46883\/onc.2020.3411.0502","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T14:12:00Z","timestamp":1644502320000},"page":"502","source":"Crossref","is-referenced-by-count":3,"title":["FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma"],"prefix":"10.46883","member":"25947","published-online":{"date-parts":[[2020]]},"container-title":["ONCOLOGY"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T17:34:23Z","timestamp":1646933663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/fda-approves-nivolumab-plus-ipilimumab-for-previously-untreated-unresectable-malignant-pleural-mesothelioma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":0,"issue-title":["November 2020"],"journal-issue":{"issue":"3411","published-online":{"date-parts":[[2020,11,13]]},"published-print":{"date-parts":[[2020,11,12]]}},"URL":"https:\/\/doi.org\/10.46883\/onc.2020.3411.0502","relation":{},"ISSN":["0890-9091"],"issn-type":[{"value":"0890-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}